International. At its most recent meeting, the Board of Partners of E. Merck KG has appointed Stefan Oschmann (58 years old) as the new Chairman of the Board of Directors and CEO of Merck KGaA. The appointment will take effect at the end of the Ordinary General Meeting of April 29, 2016.
Stefan Oschmann will replace Karl-Ludwig Kley (64) who will retire after nine years at the helm of Merck.
Stefan Oschman has been a member of Merck's Executive Board since 2011. He was initially in charge of the pharmaceutical business before being appointed Vice Chairman of the Executive Board and Deputy General Manager in early 2015, responsible for strategy and innovation.
"Under the leadership of Karl-Ludwig Kley, Merck has gone through the greatest transformation in its nearly 350-year history. This involved the construction and expansion of no less than three strong global companies that are able to provide innovative solutions for patients and customers and safe growth and prosperity for our 40,000 employees," said Johannes Baillou, Chairman of the Board of Partners of E. Merck KG.
"We are equally pleased to have found a successor in Stefan Oschmann, whose forward-thinking and strong strategic leadership have made Merck a respected player in the industry. We are convinced that he will take the appropriate steps to position Merck in a way that will allow the company to continue to actively shape in an environment that has been undergoing scientific and digital changes."
Leave your comment